 |
|
ESC Congress 2004: Antibiotic Treatment for Secondary Prevention of Coronary Events: Results of the Azithromycin and Coronary Events Study (ACES)
August 30, 2004Results of large-scale clinical trial of antibiotic treatment to reduce heart attacks
ACES study did not reduce coronary heart disease events
Results presented during a Hot Line session at the European Society Cardiology meeting here today showed that weekly treatment for one year with azithromycin did not result in any reduction in the incidence of cardiovascular events when compared to placebo.
The Azithromycin and Coronary Events Study (ACES) enrolled 4012 participants at 28 clinical centres in the United States. Participants received either placebo or azithromycin 600mg once weekly for one year and were followed for four years. Antibiotic treatment was directed at a bacteria known as Chlamydia pneumoniae which has been found in the coronary arteries of patients with coronary heart disease (CHD).
What does the negative findings in the ACES study tell us about the Association of C. pneumoniae and heart disease? It does suggest that neither C. pneumoniae nor other bacteria susceptible to azithromycin plays an important role in the late stage disease 7of CHD. However "the trial results do not tell us anything about a possible role of C. pneumoniae in the early development or acceleration of CHD" said Dr. J. Thomas Grayston, the Principal Investigator of the ACES trial.
Dr. Grayston is a professor of Epidemiology at the University of Washington in Seattle.
Most importantly says Dr. Grayston, "The study results do not support the use of antibiotic therapy for treatment of coronary heart disease. While not as exciting as positive findings, negative findings can be important. In this case, the findings are important because in the past it was unclear whether antibiotics might have some benefit in patients with coronary heart disease and we now know that such treatment is not helpful".
*****
S Borrowdale (Seattle, US)
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2004. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology
European Society of Cardiology (ESC)
The Azithromycin and Coronary Events Study (ACES) enrolled 4012 participants at 28 clinical centres in the United States. Participants received either placebo or azithromycin 600mg once weekly for one year and were followed for four years. Antibiotic treatment was directed at a bacteria known as Chlamydia pneumoniae which has been found in the coronary arteries of patients with coronary heart disease (CHD).
What does the negative findings in the ACES study tell us about the Association of C. pneumoniae and heart disease? It does suggest that neither C. pneumoniae nor other bacteria susceptible to azithromycin plays an important role in the late stage disease 7of CHD. However "the trial results do not tell us anything about a possible role of C. pneumoniae in the early development or acceleration of CHD" said Dr. J. Thomas Grayston, the Principal Investigator of the ACES trial.
Dr. Grayston is a professor of Epidemiology at the University of Washington in Seattle.
Most importantly says Dr. Grayston, "The study results do not support the use of antibiotic therapy for treatment of coronary heart disease. While not as exciting as positive findings, negative findings can be important. In this case, the findings are important because in the past it was unclear whether antibiotics might have some benefit in patients with coronary heart disease and we now know that such treatment is not helpful".
*****
S Borrowdale (Seattle, US)
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2004. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology
European Society of Cardiology (ESC)
Heart Disease Current Events and Heart Disease News RSSTraditional Risk Assessment Tools Do Not Accurately Predict Coronary Heart Disease
The Framingham and National Cholesterol Education Program tools, NCEP, do not accurately predict coronary heart disease, according to a study performed at the Yale University School of Medicine in New Haven, CT.
Researchers engineer pancreatic cell transplants to evade immune response
In a finding that could significantly influence the way type 1 diabetes is treated, researchers at Albert Einstein College of Medicine of Yeshiva University have developed a technique for transplanting insulin-producing pancreatic cells that causes only a minimal immune response in recipients.
Safe new therapy for genetic heart disease
A new clinical trial suggests that long-term use of candesartan, a drug currently used to treat hypertension, may significantly reduce the symptoms of genetic heart disease.
Simple Model Predicts Those at Risk for Chronic Kidney Disease
Traditionally, doctors have had no clear way to predict which of their patients might be headed down the road to chronic kidney disease (CKD).
Eating at buffets plus not exercising equals obesity in rural America
In small towns in the Midwestern United States, people who eat out often at buffets and cafeterias and who perceive their community to be unpleasant for physical activity are more likely to be obese.
Researchers compile 'molecular manual' for 100s of inherited diseases
An international research team has compiled the first catalogue of tissue-specific pathologies underlying hundreds of inherited diseases.
Patients with severe psoriasis need evaluation of heart disease risk
According to new recommendations in the December 10 issue of The American Journal of Cardiology (AJC), published by Elsevier, new research is called for and patients with severe forms of the skin disease psoriasis should receive evaluation and possible treatment to reduce their risk of coronary artery disease (CAD).
Rare disease provides clues about enzyme role in arrhythmias
A University of Iowa study provides insight into a calcium-sensing enzyme already known to play a role in irregular heartbeats and other critical functions.
Cellular 'brakes' may slow memory process in aging brains
University of Florida researchers may have discovered why some brain cells necessary for healthy memory can survive old age or disease, while similar cells hardly a hairsbreadth away die.
Gene therapy effective treatment against gum disease
Scientists at the University of Michigan have shown that gene therapy can be used to successfully stop the development of periodontal disease, the leading cause of tooth loss in adults.
More Heart Disease Current Events and Heart Disease News Articles
 | Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty (PATHOPHYSIOLOGY OF HEART DISEASE (LILLY)) Completely rewritten and updated for its Fourth Edition, this best-selling text is a comprehensive, clear, concise, and easy-to-understand introduction to cardiovascular diseases. It is written by internationally recognized Harvard Medical School faculty and select medical students, and is the best text to bridge basic physiology with clinical care of patients. This edition provides updated... |
 | NO More Heart Disease: How Nitric Oxide Can Prevent--Even Reverse--Heart Disease and Strokes by Louis Ignarro Dr. Louis Ignarro discovered "the atom" of cardiovascular health--a tiny molecule called Nitric Oxide. NO, as it is known by chemists, is a signaling molecule produced by the body, and is a vasodilator that helps control blood flow to every part of the body. Dr. Ignarro's findings led to the development of Viagra. Nitric Oxide has a beneficial effect on the cardiovascular system as well.NO... |
 | Prevent and Reverse Heart Disease: The Revolutionary, Scientifically Proven, Nutrition-Based Cure by Caldwell B. Esselstyn A powerful call for a paradigm shift in heart disease therapy. Based on the groundbreaking results of a twenty-year nutritional study by Dr. Esselstyn, a preeminent researcher and clinician, this book illustrates that a plant-based, oil-free diet can not only prevent and stop the progression of heart disease but can also reverse its effects. The proof lies in the incredible outcomes for patients... |
 | Reverse Heart Disease Now: Stop Deadly Cardiovascular Plaque Before It's Too Late by Sinatra, James C., M.D. Roberts While most books focus solely on the role of cholesterol in heart disease, Reverse Heart Disease Now draws on new research that points to the surprising other causes. Two leading cardiologists draw on their collective fifty years of clinical cardiology research to show you how to combine the benefits of modern medicine, over-the-counter vitamins and supplements, and simple lifestyle changes to... |
 | Dr. Dean Ornish's Program for Reversing Heart Disease by Dr Dean Ornish Dr. Dean Ornish was the first person to offer scientific proof that heart disease often can be halted or even reversed simply by changing your diet and lifestyle. Based on his internationally acclaimed scientific studies, Dr. Ornish's program yielded amazing results. Participants often reduced or discontinued medications; their chest pains usually diminished or disappeared; they felt more... |
 | Reversing Heart Disease: A Vital New Program to Help Prevent, Treat, and Eliminate Cardiac Problems Without Surgery by Julian M. Whitaker Here is an update of the complete guide to cardiac carepacked with new ways to conquer heart disease without drugs or bypass surgery! Hundreds of thousands of heart patients have used Dr. Julian Whitakers best-selling Reversing Heart Disease to successfully deal with cardiac problems naturally. Now, drawing on nearly 20 years of experience at his Whitaker Wellness Institute, Dr. Whitaker examines... |
 | Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 2 Volume Set Established since 1968 as a classic pediatric cardiology text, this two-volume work is now in its Seventh Edition. Leading international experts describe state-of-the-art diagnostic and interventional techniques for young patients with congenital and acquired heart diseases and for adult survivors of congenital heart disease. This edition's section on pediatric cardiac intensive care has new... |
 | The No Bull Book on Heart Disease: Real Answers to Winning Back Your Heart and Health by Joel Okner, Jeremy Clorfene Written in plain English by a board-certified cardiologist and a clinical psychologist who specializes in heart disease, this is a practical “what-to-expect” guide that will help readers cope with their confusion, fear, and lack of information, as well as decode what doctors really mean when they describe certain cardiac procedures, treatments, and medications. The authors clearly explain... |
| Dr. Dean Ornish's Program for Reversing Heart Disease by Dr. Dean Ornish | |
 | Congenital Heart Disease in Adults (Congenital Heart Disease in Adults (Perloff/Child)) by Joseph K. Perloff, John S. Child, Jamil Aboulhosn Dr. Perloff, the founding father of the field of adult congenital heart disease, presents a decade's worth of research and clinical data in the completely redefined 3rd edition to bring you the most current information. With advances in diagnosis and treatment in children, more and more of those with CHD survive well into adulthood. Expert contributors in various fields offer a... |
| © 2009 BrightSurf.com |